Merit Medical Systems (NASDAQ:MMSI) Stock Rating Upgraded by Zacks Research

Merit Medical Systems (NASDAQ:MMSI) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports. Zacks Research also issued estimates for Merit Medical Systems’ Q4 2026 earnings at $0.98 EPS, FY2026 earnings at $3.73 EPS, Q1 2027 earnings at $0.88 EPS, Q2 2027 earnings at $1.02 EPS, Q3 2027 earnings at $1.01 EPS, Q4 2027 earnings at $1.10 EPS, FY2027 earnings at $4.01 EPS, Q1 2028 earnings at $0.95 EPS, Q2 2028 earnings at $1.11 EPS and FY2028 earnings at $4.32 EPS.

Several other analysts also recently weighed in on the company. BTIG Research reiterated a “buy” rating and issued a $105.00 price objective on shares of Merit Medical Systems in a research report on Tuesday, August 11th. Bank of America raised their target price on shares of Merit Medical Systems from $92.00 to $97.00 and gave the stock a “neutral” rating in a report on Thursday, August 13th. Weiss Ratings raised shares of Merit Medical Systems from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. Raymond James Financial reiterated an “outperform” rating and set a $100.00 price target on shares of Merit Medical Systems in a report on Friday, July 31st. Finally, Robert W. Baird set a $98.00 price target on shares of Merit Medical Systems in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $100.00.

Merit Medical Systems Stock Down 0.6%

Shares of NASDAQ:MMSI opened at $90.54 on Tuesday. The stock has a market capitalization of $5.41 billion, a P/E ratio of 37.41, a price-to-earnings-growth ratio of 2.27 and a beta of 0.49. The stock’s 50-day moving average price is $78.85 and its 200-day moving average price is $72.74. The company has a current ratio of 4.20, a quick ratio of 2.79 and a debt-to-equity ratio of 0.44. Merit Medical Systems has a 12-month low of $59.74 and a 12-month high of $94.75.

Merit Medical Systems (NASDAQ:MMSI) last released its earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.96 by $0.23. The company had revenue of $418.84 million during the quarter, compared to analyst estimates of $405.25 million. Merit Medical Systems had a return on equity of 13.75% and a net margin of 9.22%.Merit Medical Systems’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.01 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. On average, equities analysts anticipate that Merit Medical Systems will post 3.84 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in MMSI. Los Angeles Capital Management LLC purchased a new stake in shares of Merit Medical Systems in the 4th quarter worth about $25,000. Kilter Group LLC bought a new stake in shares of Merit Medical Systems during the 2nd quarter valued at about $25,000. Torren Management LLC purchased a new position in shares of Merit Medical Systems during the fourth quarter valued at about $38,000. Covestor Ltd increased its position in shares of Merit Medical Systems by 252.6% during the fourth quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 336 shares during the period. Finally, Danske Bank A S bought a new position in Merit Medical Systems in the third quarter worth about $42,000. 99.66% of the stock is owned by hedge funds and other institutional investors.

Merit Medical Systems News Roundup

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Zacks Research raised several earnings forecasts. The firm increased its FY2026 EPS estimate to $3.73 from $3.57, FY2027 to $4.01 from $3.82, and FY2028 to $4.32 from $4.12. It also lifted estimates for Q2 2027, Q3 2027, Q1 2028, and Q2 2028. The revisions suggest improved confidence in Merit Medical’s longer-term earnings growth.
• Positive Sentiment: Longer-term earnings expectations are moving higher. The revised FY2027 and FY2028 forecasts exceed the current-year consensus estimate of roughly $3.81–$3.84 per share, reinforcing the outlook for continued earnings expansion.
• Neutral Sentiment: Short-interest data appears unusable. The report lists short interest at zero shares and describes the change as “NaN,” with a zero days-to-cover ratio. This does not provide a meaningful signal about short-selling pressure or potential short covering.
• Negative Sentiment: One near-term estimate was reduced. Zacks lowered its Q4 2026 EPS forecast slightly to $0.98 from $0.99. While the change is minor, it offsets some of the broader positive revisions and indicates limited near-term earnings impact.
• Negative Sentiment: Valuation leaves less room for disappointment. Merit Medical’s shares recently traded near their 52-week high, with a P/E ratio above 37 and a PEG ratio above 2. Stronger earnings expectations are supportive, but the premium valuation could weigh on the stock if results or guidance fall short.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.